✨ Free AI Report
BioCardia, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview BioCardia, Inc.
Research Preview

BioCardia, Inc.: Business Overview, Financials & Competitive Analysis

BioCardia, Inc. is a clinical-stage regenerative medicine company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's pipeline includes multi...

Analyst-debate audio for BioCardia, Inc.

AskCyborg analysts argue the bull and bear cases for BioCardia, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BioCardia, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Clinical-stage cell therapy innovator with near-term Phase III inflection potential, offset by execution risk and capital...

Read the full analyst-debate transcript →
Industry Gene Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest BioCardia, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BioCardia, Inc. Overview

Pro stress-test →

BioCardia, Inc. is a clinical-stage regenerative medicine company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's pipeline includes multiple cell therapy candidates at varying clinical stages, with its lead program in late-stage development.

Strategic Profile

Pro stress-test →

The company's lead product CardiAMP is an autologous mononuclear cell therapy system in Phase III clinical trial for ischemic heart failure with reduced ejection fraction and refractory angina. BioCardia also offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart and Morph deflectable guides and sheaths products.

Competitive Landscape

Pro stress-test →

BioCardia competes in regenerative medicine and cell therapy for cardiovascular disease against both large pharma with cardiovascular franchises and smaller biotech firms developing cell therapies. Direct competitors include companies pursuing autologous or allogeneic cell therapies for heart failure, such as Vericel, Mesoblast, and academic-backed programs. The Helix platform provides differentiation versus competitors lacking minimally invasive delivery systems.

Industry Context

BioCardia, Inc. operates in Gene Therapy.

Key facts

Founded: 1999 (re-established 2016 via reverse merger) · Headquarters: Sunnyvale, California · Employees: 40 · Revenue: Estimated <$1M (clinical-stage company with minimal product revenue as of 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for BioCardia, Inc..

+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BioCardia, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

VericelCell therapy company focused on regenerative medicine→MesoblastAllogeneic cell therapy developer→Capricor TherapeuticsCardiosphere-derived cell therapy for heart disease→

Compare BioCardia, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BioCardia, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about BioCardia, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BioCardia, Inc. and its top competitor on Cyborg Score”
“What did BioCardia, Inc. do this quarter?”
“Is BioCardia, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BioCardia, Inc. do?+
BioCardia, Inc. is a clinical-stage regenerative medicine company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's pipeline includes multi...
What is BioCardia, Inc.'s Cyborg Score?+
BioCardia, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BioCardia, Inc.'s main competitors?+
Named competitors include Vericel, Mesoblast, Capricor Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full BioCardia, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BioCardia, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BioCardia, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.8Vericel Corporation7Mesoblast Limited